Investigation of drug synergy in an in vivo xenograft model, evaluation of the impact of EGFR CNG on survival in a cohort of ESCC patients treated with docetaxel monotherapy, as well as extension of investigation to other EGFR inhibitors would also be beneficial. The gene discussed is EGFR; the disease is esophageal squamous cell carcinoma.